Related Experiment Video

Updated: Jun 13, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer

Sang-Haak Lee1, Tingan Chen, Jun Zhou

  • 1Division of Pulmonology, Department of Internal Medicine, St. Paul's Hospital, Catholic University of Korea, Seoul.

Clinical Lung Cancer
|May 5, 2010
PubMed
Abstract

Insights

Enzastaurin effectively inhibits Protein Kinase C-beta2 (PKCbeta2) in lung cancer cell lines, regardless of PRKCB1 variants. This suggests its potential as a targeted therapy for non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinase C-beta2 (PKCbeta2) is implicated in cancer cell proliferation and survival.
  • Enzastaurin is a selective inhibitor of PKCbeta2, with prior preclinical activity in various cancers.
  • Limited efficacy of enzastaurin as a single agent in advanced non-small-cell lung cancer (NSCLC) necessitates further investigation.

Purpose of the Study:

  • To investigate the presence of biologically relevant PRKCB1 variants in lung cancer cell lines.
  • To assess the impact of these variants on enzastaurin's antiproliferative and kinase inhibitory activity.
  • To evaluate enzastaurin's efficacy in both NSCLC and small-cell lung cancer (SCLC) cell lines.

Main Methods:

  • Exon sequencing of the PRKCB1 gene in lung cancer cell lines.
  • Immunoblotting to assess protein levels and phosphorylation.
  • Cytotoxicity assays to determine antiproliferative effects.
  • Kinase inhibition assays to measure phosphorylation inhibition.

Main Results:

  • A single nucleotide variant (T40I) was identified in PKCbeta2, but it did not alter kinase activity or enzastaurin's efficacy.
  • Enzastaurin demonstrated potent and consistent inhibition of PKCbeta2 phosphorylation and downstream signaling.
  • The drug exhibited similar activity across both NSCLC and SCLC cell lines, with IC50 values in the nanomolar range.

Conclusions:

  • PRKCB1 variants do not appear to affect enzastaurin's activity in lung cancer cell lines.
  • Enzastaurin effectively inhibits PKCbeta2 and downstream signaling pathways.
  • Measuring phosphorylation of PKCbeta2 and related molecules could serve as a pharmacodynamic marker for enzastaurin's in vivo target engagement.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...